A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Adalimumab-Adaz (Adalimumab)

Adalimumab-Adaz suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

First FDA approval2023-07-01
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$32.5M in CY2024 Part D spend12K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$1593.32/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1593.32
Across all dosage forms in distribution.
Highest NADAC
$1593.32
Range is tight.
Plans with PA
54 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Adalimumab-Adaz used for?

Adalimumab-Adaz suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

Is there a generic for Adalimumab-Adaz?

No. Adalimumab-Adaz is brand-only with no generic equivalents currently in market.

How much does my plan pay for Adalimumab-Adaz?

Across 329 Part D plans, Adalimumab-Adaz averages $1593.32/unit (NADAC). Lowest available: $1593.32/unit. Highest in distribution: $1593.32/unit.

Is Adalimumab-Adaz on the FDA shortage list?

Adalimumab-Adaz has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Tumor Necrosis Factor Blocker6 alternatives in D1
01
Adalimumab-Aqvh
Brand: YUSIMRY
$604.15Lowest NADAC
0Generic mfrs
$1.0MCY24 Part D spend
Compare →
02
Adalimumab-Atto
Brand: AMJEVITA
Lowest NADAC
0Generic mfrs
$64.2MCY24 Part D spend
Compare →
03
Adalimumab-Bwwd
Brand: HADLIMA
$611.35Lowest NADAC
0Generic mfrs
$21.4MCY24 Part D spend
Compare →
04
Certolizumab Pegol
Brand: Cimzia
$6072.51Lowest NADAC
0Generic mfrs
$431.9MCY24 Part D spend
Compare →
05
Etanercept
Brand: ENBREL
$2076.23Lowest NADAC
0Generic mfrs
$5.14BCY24 Part D spend
Compare →
06
Golimumab
Brand: SIMPONI ARIA
$12974.52Lowest NADAC
0Generic mfrs
$359.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.